Fischer Seth H. Z. 4

What Happened
Seth H.Z. Fischer, a director of Esperion Therapeutics, received an award of 79,873 shares on May 28, 2026. The transaction is reported as an acquisition (code A) at $0.00 per share (total recorded value $0). This was a grant/award of shares rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-28; Form 4 filed: 2026-06-01 (filed within the typical two-business-day window).
• Transaction type/code: Award/Grant (A). Price reported: $0.00; Shares awarded: 79,873.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: Awards vest in full on the earlier of (i) May 28, 2027 and (ii) the issuer’s next annual meeting of stockholders following May 28, 2026. (Footnote F1)
• No indication in the provided data of tax withholding, a 10b5-1 plan, or a sale/transfer related to these shares.

Context
This was a compensation award (not a market buy or sale). Such grants are common for directors and typically vest over time or upon certain events; they do not by themselves signal immediate buying or selling pressure. Retail investors should treat awards as executive/board compensation rather than a direct bullish/bearish trade.